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Summary: Twelve unrelated subjects with heterozygous familial defective apolipoprotein B-100 were identified
in a group of 252 patients with type Ila hypercholesterolaemia. Approximately 5% of hypercholesterolaemia
can be explained by this mutation in the collective studied. Familial defective apolipoprotein B-100 is therefore
the most common known mutation causing primary hypercholesterolaemia. Family studies revealed an
additional 14 affected subjects. All family members with the mutation had elevated cholesterol concentrations.
In a normolipidaemic control group of 146 subjects the mutation was not present. In the affected individuals
a variable expression of total cholesterol concentrations and atherosclerosis was observed. Plasma cholesterol
ranged from 6.60 to 14.89 mmol/1 with a mean of 9.43 mmol/1. Premature atherosclerosis was present in 4
patients, while one affected woman is now 92 years old and has no symptoms of coronary heart disease or
peripheral atherosclerosis. Analysis of the haplotypes and genotypes by 3 biallelic and 1 multi-allelic DNA
marker suggests that the disorder is caused in all affected patients by the same rare allele. The fact that the
same mutant allele was also identified in other European populations and in a North American population
of Caucasian origin argues for a common European origin of this mutation.
Introduction j r . · i· . · ™ *™ · ^ j · _ jdefective apolipoprotein B-100 is a recently described
Familial defective apolipoprotein B-100 is a recently disease, only a few subjects have been described in
identified, autosomal dominantly inherited genetic the literature (3 —11). The total number of identified
disorder which leads to increased serum levels of low unrelated subjects is at the moment less than 100,
density lipoprotein (LDL) cholesterol (1). Apolipo- worldwide. The apolipoprotein B-100 mutation in-
protein B-100 is the sole protein constituent of LDL creases the LDL-cholesterol, but there exists a wide
particles and is responsible for the recognition of LDL range of LDL-cholesterol levels among the subjects,
particles by the LDL receptor. In familial defective The plasma of an individual heterozygous for the
apolipoprotein B-100, a G to A mutation at nucleic mutation contains two populations of LDL particles,
acid 10708 in exon 26 results in the substitution of The increased serum LDL concentration is due to an
glutamine for arginine at amino acid position 3500. accumulation of defective LDL particles containing
This mutation decreases the binding of LDL to the the mutant apolipoprotein B-100. The implications
LDL receptor by more than 95% and causes an for artherosclerosis of the plasma enrichment of de-
accumulation of defective LDL particles in serum (2). fectively binding LDL particles cannot be determined
The prevalence of familial defective apolipoprotein B- with certainty from the limited number of identified
100 was estimated to be approximately one in 500 subjects.
(3 — 5), making it one of the most common single-
gene mutations. The high frequency and the occur- Recently we described a method for identifying sub-
rence of the mutation in several different populations jects with familial defective apolipoprotein B-100 (12).
raise questions concerning its origin. Because familial We report here the results of screening 398 subjects.
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The biochemical and clinical data of 12 unrelated
subjects heterozygous for familial defective apolipo-
protein B-100 and their affected and unaffected family
members is presented.
Subjects and Methods
Subjects
A group of 252 unrelated patients with type Ha hypercholes-
terolaemia (LDL cholesterol > 4.66 mmol/1) were investigated
for familial defective apolipoprotein B-100. All individuals were
recruited from the outpatient lipid clinic of the Institute of
Clinical Chemistry at the University of Cologne. According to
their LDL-cholesterol concentration the hypercholesterolaemic
patients were divided into three subgroups (tab. 1). By studying
the kindred of 8 affected patients, 32 additional subjects were
collected and screened for the apolipoprotein B-100 mutation.
A second group of 146 normolipidaemic subjects was also
studied for familial defective apolipoprotein B-100.
Determination of plasma lipids, l ipoproteins and
apolipoprotein E genotypes
Blood samples were obtained after an overnight fast. Total
serum cholesterol, lipoprotein cholesterol and serum triacylgly-
cerols were determined by enzymatic assays (Boehringer, Mann-
heim, Germany). Very low density lipoproteins (VLDL) were
separated by preparative ultracentrifugation according to Havel
et al. (13). High density lipoprotein (HDL) cholesterol was
determined in the VLDL-free infranatant after precipitation of
apolipoprotein B-100-containing lipoproteins (Boehringer,
Mannheim, Germany). The apolipoprotein E genotypes were
determined by the method of Hixson & Vernier (14).
Detection of the arginine^soo) —» glutamine mutat ion
Genomic DNA was prepared from total blood by using the
Triton X-100 lysis method (15). DNA was amplified by the
polymerase chain reaction and the G to A mutation at nucleic
acid 10708 was detected by restriction enzyme isoform geno-
typing. The method employed was recently described in detail
(12).
Determination of genotypes
Four DNA markers were used for the genotyping. These mark-
ers consisted of 3 biallelic restriction fragment length poly-
morphism markers (Xbal, Mspl, EcoRl){) and a multi-alleuc
marker (fig. 1). The restriction fragment length polymorphism
markers were assayed by polymerase chain reaction and diges-
tion with the restriction enzymes, following agarose gel electro-
phoresis. The multi-allelic marker consisted of a variable num-
ber of tandem repeats. The number of repeats was determined
by agarose gel electrophoresis. The used nomenclature applied
for the 3'hypervariable region was that of Boerwinkle et al.
(16). If family members of an identified subject were available,
haplotypes were constructed by analysis of segregation of the
polymorphic sites. All polymerase chain reactions were carried
out in a final volume of 100 μΐ using 1 μg DNA, 0.25 mmol/1
of each nucleotide, 2.5 units Ta^-polymerase1) (Perkin-Elmer
Cetus, Langen, Germany) and the buffer recommended by the
manufacturer of the Taq polymerase. For the Xbal- and EcoRl-
polymerase chain reaction 0.2 μηιοΐ/ΐ and 0.4 μηιοΐ/l primer
were used; for the Ms/?I-polymerase chain reaction and the
hypervariable region-polymerase chain reaction 0.15 μπιοΐ/ΐ and
0.1 μηιοΐ/l, respectively. The primer sequences are described
elsewhere (1, 16 — 18). The initial denaturation was at 94 °C for
2 minutes, followed by annealing at 55 °C for 1 minute and
extension at 72 °C for 1 minute. The next 30 cycles were per-
formed in the same way, except that the denaturing time was
changed to 1 minute.
Results
Enzymes
Taq DNA polymerase from Thermus aquaticus, EC 2.7.7.7
Restriction endonudeases EC 3.1.21.—
EcoRl from Escherichia coli BS5
Xbal from Xanthomonas campestris
Mspl from Acinotobacter Iwoffii
Moraxella species
The arginineosoo) — * glutamine mutation was not de-
tected in the normolipidaemic group. In the hyper-
cholesterolaemic group, 12 patients were identified
who were heterozygous for familial defective apoli-
poprotein B-100 (tab. 1). The mutation was found in
all 3 subgroups of LDL-cholesterol concentration.
Relatives of 8 subjects were available for family stud-
ies. Within these families we identified 14 additional
subjects with the apolipoprotein B-100 mutation. The
biochemical characteristics and the clinical signs of
atherosclerosis of the 12 index patients, their relatives
with familial defective apolipoprotein B-100 and their
unaffected relatives are summarized in table 2. All
affected subjects had elevated total cholesterol con-
centrations in plasma. The cholesterol concentrations
ranged from 6.60 mmol/1 to 14.89 mmol/1, mean value
9.43 mmol/1. Hyperlipidaemia was also found in sub-
jects without familial defective apolipoprotein B-100.
In 2 subjects, one from the F. S. family and the other
from the Ε. Κ. family, hyperlipidaemia might be sec-
ondarily caused by diabetes mellitus. The subject from
the W. E. family had moderate hypercholesterolaemia
which was first manifest postmenopausal. Hypercho-
lesterolaemia of other causes was also observed in the
H. K. and H. A. family. Premature atherosclerosis was
found in 4 of the 26 subjects with familial defective
apolipoprotein B-100. Severe coronary obstructions
warranted, in 3 patients, a coronary artery bypass
graft. The age of operation was 52 and 60 for the two
females and 20 for the male. The fourth patient had
suffered a myocardial infarction at age 61. The oldest
patient was 92 years of age and had no symptoms of
coronary heart disease or peripheral atherosclerosis.
In the unrelated probands, arcus cornea was present
in 45%, and xanthoma of the Achilles tendon or the
extensor tendon of the finger were found in 36%.
In an attempt to find the reason for the variable
degree of LDL-cholesterol elevation we determined
the apolipoprotein Ε genotypes in the 26 affected
patients (tab. 2). One patient had the genotype E2/
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Fig. 1. DNA markers for the 3'-end of the human apolipoprotein B-100 gene.
In the upper portion, the position of the restriction fragment length polymorphisms, the mutation and the hypervariable
region (HVR) are shown. The lower portion shows the length of the polymerase chain reaction fragments in base pairs
(bp) before and after digestion with the appropriate restriction enzyme.
Tab. 1. Prevalence of familial defective apolipoprotein B-100 in normolipidaemic and hypercholesterolaemic individuals
Normolipidaemic subjects
Hypercholesterolaemia type Ha
LDL-cholesterol: 4.69 - 5.70 mmol/1
LDL-cholesterol: 5.71 - 6.73 mmol/1
LDL-cholesterol: >6.73 mmol/1
Number of
screened subject
146
252
58
57
137
Frequency of mutation
absolute
0
12
3
1
8
relative (%)
4.8
5.2
1.8
5.8
E3. The most common genotype E3/E3 was detected
in 21 subjects. In 3 cases the genotype E3/E4 and in
one case the genotype E4/E4 was present. The group
of subjects with the genotype E3/E3 included patients
with moderate and severe hypercholesterolaemia.
Therefore the apolipoprotein E genotype is not re-
sponsible for the variability of LDL cholesterol ele-
vation in these patients.
The haplotypes were determined by 3 diallelic markers
and one hypervariable multi-allelic marker (fig. 1).
The hypervariable region at the 3'-end of the gene
comprises 12 resolvable alleles containing different
numbers of 15-base pair tandemly repeated sequences.
The analysis of haplotypes of the 8 kindred is illus-
trated in figure 2. In 7 of the 8 families the haplotypes
of the mutant allele were determined unambiguously.
The haplotypes of the mutant were in all cases iden-
tical, characterized by the presence of the Mspl re-
striction site (Mspl+), the absence of the Xbal (Xbal~)
and EcoRl (EcoRl~) restriction sites and 49 of the
15 base pair repeats of the hypervariable region
(HVR-49). In the remaining 5 individuals with fami-
lial defective apolipoprotein B-100, the combination
of genotypes was consistent with the presence of the
mutation on the above described haplotype.
Eur. J. Clin. Chem. Clin. Biochem. / Vol. 30,1992 / No. 11
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Fig. 2. Pedigrees and haplotype analysis of the 8 kindred with familial defective apolipoprotein B-100.
The haplotypes were constructed by analysis of segregation of 3 biallelic DNA markers (Xbal, Mspl, EcoRI) and one
hypervariable multi-allelic marker (3'hypervariable region, 3'HVR ). The haplotype of the mutant allele is encircled. The
available subjects in the families are numbered. Heterozygous familial defective apolipoprotein B-100 is shown by half-
shadowed symbols. The arrow indicates the index patients. The biochemical data are presented in table 2.
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Discussion
With the recently described modified polymerase
chain reaction technique (12) we screened 252 unre-
lated individuals with hypercholesterolaemia and 146
normolipidemic controls. In the hypercholestero-
laemic group 12 unrelated individuals heterozygous
for familial defective apolipoprotein B-100 were iden-
tified. The frequency of the mutation was, therefore,
about 5% in the hypercholesterolaemic group. In
normolipidaemic subjects the mutation was not de-
tected. Assuming a frequency of type Ila hypercho-
lesterolaemia of 5/100 (19), a crude estimate of the
frequency of familial defective apolipoprotein B-100
would be 1/400 in the general population and is thus
similar to the frequency of familial hypercholestero-
laemia which is characterized by defects in the LDL-
receptor.
The study of biochemical characteristics and signs of
atherosclerosis revealed a considerable variability of
expression in patients with heterozygous familial de-
fective apolipoprotein B-100, exemplified by patients
W. E. and S. W. (tab. 2). S. W. had severe hypercho-
lesterolaemia and premature atherosclerosis. He war-
ranted a coronary bypass graft at age 20 and had
stenosis of the carotis. In contrast, W. E. had only
moderate hypercholesterolaemia, the total cholesterol
concentrations ranging in the last 10 years from 5.70
to 7.25 mmol/1. Over the whole period she was treated
only with diet. Her HDL-cholesterol concentration
was at the lower end of the reference range for women.
The patient is now 92 years old and has no symptoms
of coronary heart disease or peripheral atheroscle-
rosis. Obviously, in patients with familial defective
apolipoprotein B-100, atherosclerosis was more ad-
vanced in those with severe hypercholesterolaemia
than in patients with moderate hypercholesterolae-
mia. In addition to hypercholesterolaemia, other risk
factors, such as smoking as seen in patients S. W. and
E. K., may contribute to the progression of athero-
sclerosis. In summary, it is not the apolipoprotein B-
100 mutation per se but the degree of cholesterol
elevation and the combination with other risk factors
that seem to determine the atherosclerosis risk.
Premature atherosclerosis was found in only 4 out of
26 cases. Compared with the atherosclerosis risk of
familial hypercholesterolaemia (20), it seems that the
risk in patients with familial defective apolipoprotein
B-100 might be somewhat lower, even in patients with
severe hypercholesterolaemia. For example, athero-
sclerosis was present in only one of 4 females older
than 60 years with total cholesterol concentrations
near or above 10.36 mmol/1. In familial hypercholes-
terolaemia, HDL cholesterol concentrations are
slightly lower on the average than those in normal
subjects (20). In the patients studied with familial
defective apolipoprotein B-100, the mean HDL cho-
lesterol was 1.26 mmol/1 and is thus similar to that
of normal subjects. The higher HDL-cholesterol con-
centration of subjects with familial defective apoli-
poprotein B-100 in comparison with familial hyper-
cholesterolaemia might be a reason for the possibly
lower atherosclerosis risk. However, more patients
have to be evaluated to estimate the atherosclerosis
risk.
The variability of biochemical and clinical character-
istics within families was much less than between
unrelated subjects. For example, in the S.W. family
all affected persons had severe hypercholesterolaemia,
and premature atherosclerosis was present in a second
case (tab. 2). On the other hand, all affected individ-
uals of the W. E. family had total cholesterol concen-
trations below the mean value of the unrelated af-
fected subjects, and in 2 cases the concentrations were
even below the 95th percentile (19). In this family the
affected individuals were more than 60 years old and
no symptoms of atherosclerosis were observed. In an
attempt to find reasons for the variable expression of
LDL-cholesterol levels we determined the apolipopro-
tein E genotypes, but a consistent relation between
the concentration of LDL-cholesterol and the apoli-
poprotein E genotype was not observed. The apoli-
poprotein E genotype E3/E3 was detected in 21 sub-
jects. This group contained individuals with moderate
and severe hypercholesterolaemia. At the moment it
can only be speculated as to which factors influence
the expression of familial defective apolipoprotein B-
100 in these patients. But the existence of a relatively
large number of affected individuals provides an ex-
cellent model for studying the influence of other gene
loci and environmental factors on the level of LDL
cholesterol and atherosclerosis.
The families of 8 index patients were studied to de-
termine the haplotype of the arginine(35oo) —» gluta-
mine mutation (fig. 2). Seven of the 8 families were
informative, and the mutation could be assigned to
the haplotype Xbal~9 Msp+, EcoRI~ and HVR-49.
In the remaining 5 index patients, the combination of
genotypes was consistent with the described haplo-
type. Because the haplotype of the mutation is very
rare (21), it is likely that the mutation arose from a
single origin, rather than being the result of random
mutations. Identical haplotypes of the mutation have
also been described in other European populations
(6, 8, 9) and in a North American population of
European origin (3, 17). This suggests that the mu-
tation has a common European origin. The mutation
was not detected in the genetically isolated population
of Finland (22). Further studies of the frequency will
show whether a founder population exists in Europe.
Eur. J. Clin. Chem. Clin. Biochem. / Vol. 30,1992 / No. 11
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